Optimization of therapy by pharmacokinetic-pharmacodynamic analyses

Chiyo Imamura

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In cytotoxic anticancer agents, efficacy depends on tumor heterogeneity and is not evaluated immediately after administration, and toxicities are severe and life threatening such as neutropenia and thrombocytopenia. Therefore because toxicity is often more readily measured than efficacy, there are more reported pharmacodynamic (PD) studies defining relationships between pharmacokinetic (PK) parameters and the toxicity. However, retrospective studies have shown that molecular targeted agent systemic exposure correlates with treatment response (efficacy and toxicity) in various cancers including renal cell carcinoma (RCC). The evidence of the relationship between PK and PD for imatinib currently exists in the treatment of leukemia and gastrointestinal stromal tumor (GIST). It is important to evaluate the relationship between PK and PD prospectively in clinical trials rather than extrapolating from retrospective analyses. Based on these findings, therapeutic levels should be defined for molecular targeted agents in the treatment of RCC such as that that already occurs for antiepileptic, immunosuppressive, and antibiotic agents. Optimization of systemic exposure by dose modification to eliminate individual variability can increase the probability of efficacy, decrease the probability of toxicity, or both in each RCC patient treated with molecular targeted agents.

Original languageEnglish
Title of host publicationRenal Cell Carcinoma
Subtitle of host publicationMolecular Features and Treatment Updates
PublisherSpringer Japan
Pages369-381
Number of pages13
ISBN (Electronic)9784431555315
ISBN (Print)9784431555308
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Pharmacodynamics
Pharmacokinetics
Renal Cell Carcinoma
Toxicity
Gastrointestinal Stromal Tumors
Cytotoxins
Immunosuppressive Agents
Tumors
Neutropenia
Thrombocytopenia
Antineoplastic Agents
Anticonvulsants
Cells
Neoplasms
Leukemia
Therapeutics
Retrospective Studies
Clinical Trials
Anti-Bacterial Agents

Keywords

  • Mammalian targets of rapamycin (mTOR) inhibitors
  • Pharmacodynamics
  • Pharmacokinetics
  • Renal cell carcinoma (RCC)
  • Tyrosine kinase inhibitors (TKIs)

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Imamura, C. (2017). Optimization of therapy by pharmacokinetic-pharmacodynamic analyses. In Renal Cell Carcinoma: Molecular Features and Treatment Updates (pp. 369-381). Springer Japan. https://doi.org/10.1007/978-4-431-55531-5_16

Optimization of therapy by pharmacokinetic-pharmacodynamic analyses. / Imamura, Chiyo.

Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer Japan, 2017. p. 369-381.

Research output: Chapter in Book/Report/Conference proceedingChapter

Imamura, C 2017, Optimization of therapy by pharmacokinetic-pharmacodynamic analyses. in Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer Japan, pp. 369-381. https://doi.org/10.1007/978-4-431-55531-5_16
Imamura C. Optimization of therapy by pharmacokinetic-pharmacodynamic analyses. In Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer Japan. 2017. p. 369-381 https://doi.org/10.1007/978-4-431-55531-5_16
Imamura, Chiyo. / Optimization of therapy by pharmacokinetic-pharmacodynamic analyses. Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer Japan, 2017. pp. 369-381
@inbook{ff427a3b53314b4cb62cdaa66a92e7e4,
title = "Optimization of therapy by pharmacokinetic-pharmacodynamic analyses",
abstract = "In cytotoxic anticancer agents, efficacy depends on tumor heterogeneity and is not evaluated immediately after administration, and toxicities are severe and life threatening such as neutropenia and thrombocytopenia. Therefore because toxicity is often more readily measured than efficacy, there are more reported pharmacodynamic (PD) studies defining relationships between pharmacokinetic (PK) parameters and the toxicity. However, retrospective studies have shown that molecular targeted agent systemic exposure correlates with treatment response (efficacy and toxicity) in various cancers including renal cell carcinoma (RCC). The evidence of the relationship between PK and PD for imatinib currently exists in the treatment of leukemia and gastrointestinal stromal tumor (GIST). It is important to evaluate the relationship between PK and PD prospectively in clinical trials rather than extrapolating from retrospective analyses. Based on these findings, therapeutic levels should be defined for molecular targeted agents in the treatment of RCC such as that that already occurs for antiepileptic, immunosuppressive, and antibiotic agents. Optimization of systemic exposure by dose modification to eliminate individual variability can increase the probability of efficacy, decrease the probability of toxicity, or both in each RCC patient treated with molecular targeted agents.",
keywords = "Mammalian targets of rapamycin (mTOR) inhibitors, Pharmacodynamics, Pharmacokinetics, Renal cell carcinoma (RCC), Tyrosine kinase inhibitors (TKIs)",
author = "Chiyo Imamura",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55531-5_16",
language = "English",
isbn = "9784431555308",
pages = "369--381",
booktitle = "Renal Cell Carcinoma",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Optimization of therapy by pharmacokinetic-pharmacodynamic analyses

AU - Imamura, Chiyo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In cytotoxic anticancer agents, efficacy depends on tumor heterogeneity and is not evaluated immediately after administration, and toxicities are severe and life threatening such as neutropenia and thrombocytopenia. Therefore because toxicity is often more readily measured than efficacy, there are more reported pharmacodynamic (PD) studies defining relationships between pharmacokinetic (PK) parameters and the toxicity. However, retrospective studies have shown that molecular targeted agent systemic exposure correlates with treatment response (efficacy and toxicity) in various cancers including renal cell carcinoma (RCC). The evidence of the relationship between PK and PD for imatinib currently exists in the treatment of leukemia and gastrointestinal stromal tumor (GIST). It is important to evaluate the relationship between PK and PD prospectively in clinical trials rather than extrapolating from retrospective analyses. Based on these findings, therapeutic levels should be defined for molecular targeted agents in the treatment of RCC such as that that already occurs for antiepileptic, immunosuppressive, and antibiotic agents. Optimization of systemic exposure by dose modification to eliminate individual variability can increase the probability of efficacy, decrease the probability of toxicity, or both in each RCC patient treated with molecular targeted agents.

AB - In cytotoxic anticancer agents, efficacy depends on tumor heterogeneity and is not evaluated immediately after administration, and toxicities are severe and life threatening such as neutropenia and thrombocytopenia. Therefore because toxicity is often more readily measured than efficacy, there are more reported pharmacodynamic (PD) studies defining relationships between pharmacokinetic (PK) parameters and the toxicity. However, retrospective studies have shown that molecular targeted agent systemic exposure correlates with treatment response (efficacy and toxicity) in various cancers including renal cell carcinoma (RCC). The evidence of the relationship between PK and PD for imatinib currently exists in the treatment of leukemia and gastrointestinal stromal tumor (GIST). It is important to evaluate the relationship between PK and PD prospectively in clinical trials rather than extrapolating from retrospective analyses. Based on these findings, therapeutic levels should be defined for molecular targeted agents in the treatment of RCC such as that that already occurs for antiepileptic, immunosuppressive, and antibiotic agents. Optimization of systemic exposure by dose modification to eliminate individual variability can increase the probability of efficacy, decrease the probability of toxicity, or both in each RCC patient treated with molecular targeted agents.

KW - Mammalian targets of rapamycin (mTOR) inhibitors

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Renal cell carcinoma (RCC)

KW - Tyrosine kinase inhibitors (TKIs)

UR - http://www.scopus.com/inward/record.url?scp=85019419986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019419986&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55531-5_16

DO - 10.1007/978-4-431-55531-5_16

M3 - Chapter

AN - SCOPUS:85019419986

SN - 9784431555308

SP - 369

EP - 381

BT - Renal Cell Carcinoma

PB - Springer Japan

ER -